BioArctic’s Alzheimer’s drug royalties are growing, but tougher reimbursement decisions and rising scrutiny over drug costs could slow patient access and squeeze what the company ultimately takes home. With so much depending on a small set of programs and big partners, the upside looks real—but so does the risk that a setback or new kind of treatment changes the story.Read more
BioArctic’s Alzheimer’s drug is winning attention fast, but the market may already be baking in years of smooth growth that could prove hard to deliver. See what has to go right for its lead product and partnerships to keep momentum, and what headwinds could knock expectations back down to earth.Read more
BioArctic’s Alzheimer’s drug could take off faster than many expect as more doctors push for earlier testing and easier ways for patients to take treatment at home. But the story hinges on how regulators, healthcare budgets, and trial results shape demand for a small number of key programs.Read more
No trending discussion available.
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is in phase 3 clinical trials for presymptomatic treatment; Exidavnemab, which is in phase 2 clinical trials; Lecanemab back-up, BAN2803, ND3014, and BAN2802 that are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, PD-BT2238 which are in research stage. The company has research and collaboration agreement with Eli Lilly to develop a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
